Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. 

Biotechnology

Cara Therapeutics

Christopher Posner

Stephen O’Connor

Jo Goncalves

Ryan Maynard

Beth Weinberg

Scott Terrillion

Eric Vandal

Frédérique Menzaghi

Research and Development

Clinical Operations

Leadership Team

Regulatory and Quality Assurance Team

Finance and Accounting

Teams at Cara Therapeutics

Research and Development

Clinical Operations

Leadership Team

Regulatory and Quality Assurance Team

Finance and Accounting